Fluoroquinolone use and risk factors for Clostridium difficile -: Associated disease within a veterans administration health care system

被引:85
作者
McFarland, Lynne V.
Clarridge, Jill E.
Beneda, Henry W.
Raugi, Gregory J.
机构
[1] VA Puget Sound Hlth Care Syst, Dept Hlth Serv Res & Dev, Seattle, WA 98101 USA
[2] VA Puget Sound Hlth Care Syst, Dept Infect Control, Seattle, WA 98101 USA
[3] VA Puget Sound Hlth Care Syst, Lab Serv, Seattle, WA 98101 USA
[4] VA Puget Sound Hlth Care Syst, Dermatol Sect, Primary & Specialty Serv, Seattle, WA 98101 USA
[5] Univ Washington, Sch Pharm, Dept Med Chem, Seattle, WA 98195 USA
[6] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
[7] Univ Washington, Dept Med, Div Dermatol, Seattle, WA 98195 USA
关键词
D O I
10.1086/522187
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Prompted by the changing profile of Clostridium difficile infection and the impact of formulary policies in hospitals, we performed this study when an increase in the incidence of C. difficile - associated disease was noted at our health care center (Veterans Administration Puget Sound Health Care System, Seattle, Washington). Methods. A retrospective, matched case- control study of patients presenting to the Veterans Administration Puget Sound Health Care System, Seattle, Washington during 2004 was performed. Conditional logistic analysis determined risk factors for case patients, defined as individuals with diarrhea and test results ( i. e., culture or toxin assay results) positive for C. difficile, and control subjects, defined as individuals with diarrhea and test results negative for C. difficile. Results. C. difficile - associated disease incidence was 29.2 cases per 10,000 inpatient- days. The increase in the incidence of C. difficile - associated diarrhea that paralleled increased gatifloxacin use was not attributable to use of the antimicrobial but was a reflection of seasonal variation in the rate of C. difficile - associated disease. Multivariate analysis controlling for the time at which the assay was performed, the age of the patient, ward, and source of acquisition ( community- acquired vs. nosocomial disease) found 6 significant risk factors for C. difficile - associated diarrhea: receipt of clindamycin ( adjusted odds ratio [ aOR], 29.9; 95% confidence interval [ CI], 3.58 - 249.4), receipt of penicillin ( aOR, 4.1; 95% CI, 1.2 - 13.9), having a lower intestinal condition ( aOR, 2.8; 95% CI, 1.3-6.1), total number of antibiotics received ( aOR, 1.4; 95% CI, 1.1 - 1.7), number of prior hospital admissions ( aOR, 1.3; 95% CI, 1.1 - 1.6), and number of comorbid conditions ( aOR, 1.3; 95% CI, 1.1 - 1.5). Conclusions. The increase in the number of cases of C. difficile - associated disease was not attributable to a formulary change of fluoroquinolones; instead, the incidence was within expected seasonal variations for C. difficile associated disease. Recognition of community- acquired cases and the use of culture may help to identify additional cases of C. difficile - associated disease. Early diagnosis and treatment of C. difficile cases may shorten the duration of hospital stays and reduce the number of outbreaks and readmissions, mortality, and other consequences of C. difficile infection.
引用
收藏
页码:1141 / 1151
页数:11
相关论文
共 14 条
[1]   Risk factors and mortality associated with Clostridium difficile-associated diarrhoea at a VA hospital [J].
Changela, U ;
Cannon, JP ;
Aneziokoro, C ;
Shah, PS ;
Thottapurathu, L ;
Lentino, J .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 24 (06) :562-566
[2]   Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease [J].
Dial, S ;
Delaney, JAC ;
Barkun, AN ;
Suissa, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (23) :2989-2995
[3]   Recurrent Clostridium difficile diarrhea: Characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial [J].
Fekety, R ;
McFarland, LV ;
Surawicz, CM ;
Greenberg, RN ;
Elmer, GW ;
Mulligan, ME .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (03) :324-333
[4]   Detection of Clostridium difficile cytotoxin and Clostridium perfringens enterotoxin in cases of diarrhoea in the community [J].
Forward, LJ ;
Tompkins, DS ;
Brett, MM .
JOURNAL OF MEDICAL MICROBIOLOGY, 2003, 52 (09) :753-757
[5]   Outbreak of Clostridium difficile infection in a long-term care facility:: Association with gatifloxacin use [J].
Gaynes, R ;
Rimland, D ;
Killum, E ;
Lowery, HK ;
Johnson, TM ;
Killgore, G ;
Tenover, FC .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (05) :640-645
[6]   What is an appropriate control group to identify risk factors for Clostridium difficile-associated diarrhoea? [J].
Guyot, A ;
Barrett, SP .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (05) :747-748
[7]   Antibiotics and Clostridium difficile diarrhea in the ambulatory care setting [J].
Levy, DG ;
Stergachis, A ;
McFarland, LV ;
Van Vorst, K ;
Graham, DJ ;
Johnson, ES ;
Park, BJ ;
Shatin, D ;
Clouse, JC ;
Elmer, GW .
CLINICAL THERAPEUTICS, 2000, 22 (01) :91-102
[8]  
McFarland Lynne V., 2000, Microbial Ecology in Health and Disease, V12, P193, DOI 10.1080/08910600050216183
[9]   Clostridium difficile among hospitalized patients receiving antibiotics:: A case-control study [J].
Modena, S ;
Bearelly, D ;
Swartz, K ;
Friedenberg, FK .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2005, 26 (08) :685-690
[10]   Clostridium difficile-associated diarrhea in a VA medical center:: Clustering of cases, association with antibiotic usage, and impact on HIV-infected patients [J].
Mody, LR ;
Smith, SM ;
Dever, LL .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2001, 22 (01) :42-45